A cardiovascular prognosis evaluation trial of semaglutide in the treatment of T2DM reported that administration of semaglutide reduced the cardiovascular prognostic risk (110)
Beyond sleep, it influences neurotransmitter activity, hormonal rhythms, circadian behavior, and stress responses, suggesting potential therapeutic uses for sleep disorders, pain, and withdrawal syndromes
JAMA 314 (10), 10391051 (2015)
Generic dietary advice falls short for GLP-1 users because it doesn't account for the unique metabolic changes these medications create
This raises concerns about equity given the costs of these drugs, as well as the adequacy of supervision of treatment. For the study, researchers used data from the Smoking Toolkit Study, an ongoing survey Overall, 4.5% of participants reported using one of the medications in the past year for any reason
The Ozempic lawsuit, filed against pharmaceutical giants Novo Nordisk and Eli Lilly, alleged that the drugs, both Glucagon-like peptide 1 (GLP-1) agonists, caused severe gastrointestinal issues.